Demonstrates improved tumor imaging in bladder cancer, suggesting enhanced diagnostic accuracy.
Bladder cancer (BC) is a highly prevalent malignant tumor of the urinary system with high recurrence and mortality rates. Currently, urine cytology and imaging techniques exhibit insufficient sensitivity for low-grade early tumors, while clinically used surgery navigation agents suffer from short tumor retention time. To address these limitations, this study develops a solid-state fluorescent probe, HPQ-TH-BI-Cys, enabling a specific response to cysteine (Cys) for precise identification and long-term imaging of bladder cancer. The solid-state fluorophore (HPQ-TH-BI) is designed by incorporating thiophene and benzoindole moieties into the HPQ core, forming a synergistic extended π-conjugated system that shifts the emission wavelength to the near-infrared region (750 nm). Using an acrylate group as the recognition unit, the probe (HPQ-TH-BI-Cys) undergoes specific cleavage in the presence of Cys, releasing HPQ-TH-BI, which is solid-state in water and shows long-term fluorescence. The cell experiments demonstrate that HPQ-TH-BI-Cys monitors dynamic changes in Cys concentrations and accurately distinguishes between normal cells and cancer cells. In vivo imaging experiments further reveal that the probe not only performs well in a mouse subcutaneous tumor model but also exhibits outstanding performance in an orthotopic bladder cancer model. Compared with the clinically used indocyanine green (ICG), HPQ-TH-BI-Cys provides higher accuracy for tumor imaging and longer imaging time, which offers a promising imaging tool for precise diagnosis and surgical navigation of bladder cancer.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: